Monogenic diabetes (MD) accounts for 1–2% of all diabetes cases. Because of its wide
phenotypic spectrum, MD is often misdiagnosed as type 1 or type 2 diabetes. While clinical …

Aim Monogenic diabetes (MD) represents 5–7% of antibody-negative diabetes cases and is
a heterogeneous group of disorders. Methods We used targeted next-generation …

Abstract Background Monogenic diabetes (MgD) accounts for 1–2% of all diabetes cases. In
adults, MgD is difficult to distinguish from common diabetes causes. We assessed the …

Aim Identification of monogenic diabetes (MgD) conveys benefits for patients' care.
Algorithms for selecting the patients to be genetically tested have been established in …

Aim We aimed to investigate molecular genetic basis of monogenic diabetes (DM) and novel
responsible candidate genes with targeted Next Generation Sequencing (NGS) and Whole …

Aims Diabetes is increasing globally and Asia is the epicenter. Among those with young-
onset diabetes (< 45 years), the prevalence of monogenic diabetes is estimated to be non …

Monogenic forms of diabetes present opportunities for precision medicine as identification of
the underlying genetic cause has implications for treatment and prognosis. However …

Background Diagnosis of monogenic diabetes has important clinical implications for
treatment and health expenditure. However, its prevalence remains to be specified in many …

Background Monogenic diabetes presents opportunities for precision medicine but is
underdiagnosed. This review systematically assessed the evidence for (1) clinical criteria …

Introduction: Monogenic diabetes (MD) accounts for 3%–6% of all cases of diabetes. This
prevalence is underestimated due to its overlapping clinical features with type 1 and type 2 …